Microbiological process for the production of bee bread

A biotechnological process using Lactobacillus kunkeei strains and yeasts to ferment pollen replicates natural fermentation conditions, enhancing nutritional and organoleptic properties, addressing the supply and quality issues of bee bread production.

JP7578582B2Active Publication Date: 2024-11-06GIULIANI SPA
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021500421
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-07-16
Filing Date
2019-07-16
Publication Date
2024-11-06
Estimated Expiration
2039-07-16

AI Technical Summary

Technical Problem

The existing methods for producing bee bread are insufficient to meet market demand due to the instability of fresh pollen, which can stimulate mycotoxin production and require costly preservation methods like freezing or drying, while natural bee bread production is limited and damages bee hives.

Method used

A biotechnological process using selected lactic acid bacteria, particularly Lactobacillus kunkeei strains PF12, PF15, and PL13, combined with yeasts, to ferment pollen, replicating natural fermentation conditions and enhancing nutritional and organoleptic properties.

Benefits of technology

The process produces bee bread with higher nutritional value, longer shelf life, and improved organoleptic properties, suitable for dietary supplements and food formulations, addressing the supply limitations and quality issues of natural bee bread.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007578582000013
    Figure 0007578582000013
  • Figure 0007578582000014
    Figure 0007578582000014
  • Figure 0007578582000015
    Figure 0007578582000015
Patent Text Reader

Abstract

The present invention relates to a biotechnological process for the production of fermented pollen, comprising inoculating pollen with at least one lactic acid bacterium of the species Lactobacillus kunkeei selected from Lactobacillus kunkeei PF12 (DSM 32483), PF13 (DSM 32485), and / or PL13 (DSM 32844), and fermenting the pollen inoculated with said lactic acid bacterium. The resulting fermented pollen has nutritional and organoleptic properties similar to those of bee bread naturally produced in beehives and finds application in the fields of food and dietary supplements. The present invention further encompasses Lactobacillus kunkeei PF12 (DSM 32483), PF13 (DSM 32485), and / or PL13 (DSM 32844) themselves, as well as compositions comprising these strains. [Selected Figure] Figure 6A
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a microbiological process for the production of bee bread.

[0002] The present invention comes from the field of biotechnological processes for the production of nutrition, diet or food products.

[0003] In particular, the present invention relates to a biotechnological process for the production of fermented pollen similar to the bee bread produced naturally in beehives. [Background technology]

[0004] Pollen is the embryonic element of the male stamen of flowering plants, consisting of a powdery form in a sac placed at the end of the flower's stamen, a microscopic structure to which plants entrust the transport of reproductive cells. It is collected by honeybees and used for the production of royal jelly and for feeding their larvae.

[0005] In nature, pollen is the main source of proteins, lipids, sterols, minerals and vitamins for the honey bee (Apis mellifera L.), whilst in the food and dietary sector it has become an object of increasing interest due to its high nutritional content.

[0006] Bees collect pollen from plant inflorescences or from the environment and deposit it in the honeycomb honeycomb where it is mixed with nectar, honeybee nectar and glandular secretions to form granules that constitute the main protein source for the larval forms and adult bees.

[0007] The pollen inside the honeybee hive undergoes a series of biochemical transformations, mainly by lactic acid bacteria and other microorganisms. The pollen fermented inside the honeycomb is called "bee bread" (Non-Patent Document 1).

[0008] Bee bread has a different composition with respect to primary pollen after undergoing biochemical modifications such as a reduction in complex polysaccharides, changes in the amino acid, protein and lipid profile and an increase in simple carbohydrates and an increase in titratable acidity (Non-Patent Document 2; Non-Patent Document 3; Non-Patent Document 4).

[0009] These changes make bee bread a microbiologically stable environment, and furthermore pollen fermentation in the hive increases its digestibility and nutritional value compared to fresh pollen.

[0010] The nutritional and functional properties of bee bread, such as antioxidant, anti-inflammatory, hepatoprotective, anti-atherosclerotic, and immunomodulatory activities, make it a suitable product for the human diet (5; 6; 7).

[0011] However, the amount of bee bread available is insufficient compared to market demand, because its removal from the beehives is expensive and can damage the structure of the beehive, and in any case, the amount present in the beehives cannot meet the growing market demand. This shortage of the product determines the high market price.

[0012] To overcome these limitations and shortcomings, honeybee pollen is collected directly from forager bees at the entrance to the hive with the help of "pollen traps," which consist of grids that hold the pollen on a surface.

[0013] However, unlike bee bread, which does not require any kind of conditioning, fresh pollen is not a stable substrate and can stimulate the production of mycotoxins.

[0014] Therefore, freshly collected pollen must be dried or frozen before storage.

[0015] However, drying at temperatures above 35°C has been shown to cause losses of nutrients and volatile compounds, while freezing is costly to produce.

[0016] A compromise between the two techniques is represented by low temperature dehumidification. However, this technique has proven to be less effective than freezing in preserving the organoleptic and nutritional properties of bee bread.

[0017] Thus, currently there is felt a need to have bee bread of alternative origin having similar organoleptic and nutritional properties as the fresh product, in sufficient quantities to meet the market needs.

[0018] In view of the above, an industrial process for the manufacture of bee bread, which makes it possible to obtain a quantity of product suitable for market needs whilst protecting the structure of the beehive, is part of the general subject matter of the present invention. [Prior art documents] [Non-patent literature]

[0019] [Non-Patent Document 1] Vasquez & Olofsson, 2009 [Non-Patent Document 2] Lee et al., 2014 [Non-Patent Document 3] Human and Nicolson, 2006 [Non-Patent Document 4] Andelkovic et al., 2012 [Non-Patent Document 5] Markiewicz-Zukowska et al.,2013 [Non-Patent Document 6] Nagai et al., 2004 [Non-Patent Document 7] Denisow and Denisow - Pietrzyk,2016 Summary of the Invention [Problem to be solved by the invention]

[0020] One of the objects of the present invention is to provide a microbiological method for producing bee bread having organoleptic properties similar to the natural product.

[0021] Another object of the present invention is to provide a biotechnological process for the production of bee bread, which has higher nutritional and functional value than fresh pollen. [Means for solving the problem]

[0022] The present invention derives from the observation that fermentation of pollen with selected bacterial lactic acid bacteria reproduces environmental conditions similar to those typical of the natural fermentation that leads to the formation of bee bread.

[0023] In particular, it has been found that fermentation of pollen with certain bacterial fructose lactic acid bacteria in combination with certain yeasts results in fermented pollen which can be assimilated in naturally produced bbq bread, increasing production yields for the same starting amount of pollen.

[0024] The applicant has therefore identified selected strains of lactic acid bacteria that use fructose as the preferred substrate relative to glucose as a carbon source for the production of bee bread and has found that they can be used within a biotechnological process to produce bacterial or semi-bacterial bee bread.

[0025] According to a first aspect, the present invention provides a microbiological process for the production of bee bread comprising: a) preparation of inoculum and inoculation of pollen with starter lactic acid bacteria using fructose as the preferred substrate relative to glucose as the carbon source for the production of bee bread; and b) The process of pollen fermentation, Said process is characterized in that the inoculated starter lactic acid bacteria belong to the species Lactobacillus kunkeei.

[0026] The inventors have also found that Lactobacillus kunkeei strains PF12, PF15 and PL13 and mixtures thereof are particularly suitable as starter lactic acid bacteria for the process of the invention.

[0027] Advantageously, the bee bread obtained by the biotechnological process of the present invention is more nutritious and has a longer shelf life than pollen of natural origin.

[0028] The bee bread obtained from the process of the present invention also has a higher nutritional value than the pollen used as starting material for the process.

[0029] In particular, the bee bread or fermented pollen obtained by the microbiological / biotechnological process of the present invention has a higher total free amino acid and peptide content, as well as a higher digestible protein content, than the unfermented pollen used as starting material.

[0030] Additionally, the resulting bee bread or fermented pollen typically has higher levels of soluble free phenolic compounds than the starting pollen, which provide cellular antioxidant activity.

[0031] The combination of nutritional and long-lasting characteristics of the bee bread obtained with this process makes it appreciable in nutritional and dietary contexts and suitable for dietary supplement, diet or food formulations.

[0032] Advantageously, the bee bread obtained with this process has a chemical composition typical of bee bread obtained by protecting the hive structure.

[0033] According to a second aspect, the present invention provides bee bread or fermented pollen obtainable by a process defined by any one of the embodiments described herein.

[0034] According to a third aspect of the invention, a composition comprises bee bread or fermented pollen obtained by the method described herein and an edible carrier.

[0035] A further object of the present invention are selected lactic acid bacteria belonging to the species Lactobacillus kunkeei, preferably selected from PF12, PF15 and PL13 and mixtures thereof.

[0036] According to one aspect, the present invention relates to three bacterial strains belonging to the species Lactobacillus kunkeei, wherein the strains are: Lactobacillus kunkeei PF12 was deposited on July 4, 2018 at the international depository centre Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH with accession number DSM 32843; Lactobacillus kunkeei PF15 was deposited on July 4, 2018 at the international depository centre Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH with accession number DSM 32845; Lactobacillus kunkeei PL13 was deposited on July 4, 2018 at the international depository centre Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH with accession number DSM 32844;

[0037] The three previously identified strains, accompanied by certificates, have been deposited with Giuliani SpA, the company name of the current rights holder.

[0038] The features and advantages of the present invention will become apparent from the accompanying drawings, in which: [Brief description of the drawings]

[0039] [Figure 1] Figure 1 is a graph showing cell density values ​​of lactic acid bacteria (LogCFU g-1) (solid lines) and titratable acidity (mL 0.1 M NaOH 10 g-1) (TTA) (dashed lines) during 9 days of incubation at 30 °C for pollen inoculated with a mixed starter (composed of Lactobacillus kunkeei PF12, PL13 and PF15 and Hanseniaspora uvarum AN8Y27B) (solid signs) and for non-inoculated pollen subjected to spontaneous fermentation (blank signs); [Diagram 2] Figure 2 shows the concentrations (mg kg-1) of free amino acids in fresh pollen (black bars) and pollen fermented at 30 °C for 216 h (red bars) and in the mixed starter (composed of Lactobacillus kunkeei PF12, PL13, PF15 and Hanseniaspora uvarum AN8Y27B); [Diagram 3] Figure 3 shows the in vitro digestibility values ​​(red bars) of proteins (expressed as % of total proteins) in fresh pollen (black bars) and pollen fermented at 30°C for 216 h (red bars) with the mixed starter (composed of Lactobacillus kunkeei PF12, PL13 and PF15 and Hanseniaspora uvarum AN8Y27B) and two curves for molecular exclusion chromatography (RP-FPLC, 214 nm) and peptide profile in fresh pollen (black bars) and pollen fermented at 30°C for 216 h (red bars) with the mixed starter (composed of Lactobacillus kunkeei PF12, PL13 and PF15 and Hanseniaspora uvarum AN8Y27B); [Figure 4]Figure 4 is a bar graph relating the concentrations (g gallic acid eq kg dry weight) of water-soluble free phenolic compounds (white bars) and methanol (grey bars) in fresh and pollen fermented for 216 h at 30 °C with a mixed starter (composed of Lactobacillus kunkeei PF12, PL13 and PF15 and Hanseniaspora uvarum AN8Y27B). [Diagram 5] Figure 5 shows a bar graph relating to cell viability on human keratinocytes NCTC2544 after induction of oxidative stress induced with H2O2 1 mM according to the test of Example 12. The cells were incubated for 16 hours with 100, 250 and 500 μg / ml of sample B, FER867, FER868, FER869, FER870 and FER871. Untreated cells (Control) Cells treated with H2O2 1 mM (H2O2 stressed cells). *(p<0.05), **(p<0.01), ***(p<0.005), ****(p<0.001). These results show the protection of the tested compounds against oxidative stress induced and highlight the remarkable antioxidant effect of the fermented bee bread obtained in the course of the invention. [Figure 6A] Figure 6A shows a bar graph relating to TNFα gene expression in human keratinocytes NCTC2544 evaluated by qRT-PCR according to Example 12. Cells were treated with RPMI 2.5% FCS (control); RPMI 2.5% FCS and 10 μg / mL LPS (control+LPS); 100, 250 and 500 μg / mL samples A (FRESH), B (control) and FER867, FER868, FER869, FER870 and FER871 at 37°C and 5% CO2 for 16 (A) and 24 hours (B). Untreated cells (control) Cells treated with 10 μg / mL LPS (LPS) Values ​​show Mean±SEM of two experiments performed in duplicate. These results show anti-inflammatory activity and highlight the remarkable anti-inflammatory effect of the fermented bee bread obtained with the process of the invention. [Figure 6B]Figure 6B shows a bar graph relating to TNFα gene expression in human keratinocytes NCTC2544 evaluated by qRT-PCR according to Example 12. Cells were treated with RPMI 2.5% FCS (control); RPMI 2.5% FCS and 10 μg / mL LPS (control+LPS); 100, 250 and 500 μg / mL samples A (FRESH), B (control) and FER867, FER868, FER869, FER870 and FER871 at 37°C and 5% CO2 for 16 (A) and 24 hours (B). Untreated cells (control) Cells treated with 10 μg / mL LPS (LPS) Values ​​show Mean±SEM of two experiments performed in duplicate. These results show anti-inflammatory activity and highlight the remarkable anti-inflammatory effect of the fermented bee bread obtained with the process of the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0040] According to a general aspect of the present invention, a microbiological method is provided for the production of fermented pollen similar to bee bread, in which a pollen-based starting material is inoculated with one or more selected strains of advantageous lactic acid bacteria of the species Lactobacillus kunkeei to effect a fermentation that substantially replicates the fermentation occurring in pollen nature stored inside the honeycomb of a beehive.

[0041] According to a general aspect, the present invention relates to a pollen fermentation process as defined in claim 1.

[0042] Further embodiments of the process according to the invention are defined in claims 2-7.

[0043] The inventors have observed that the fermented pollen obtained with the process of the invention has better nutritional characteristics both with respect to fresh pollen and with respect to bee bread naturally fermented in hives with a longer shelf life. This combination of characteristics makes the fermented pollen obtained with the process of the invention particularly suitable as a nutritional, dietary or nutraceutical product.

[0044] By way of example, the total free polyphenol content present in the fermented pollen obtained with the method of the invention is equal to 84.64 g eq. gallic acid per kg dry weight, a quantity considerably higher than the contents indicated in the literature for bee bread obtained by natural fermentation, which is equal to 8.9 to 36.52 g eq. gallic acid per kg dry weight, as described in the literature by Markiewicz-Zukowska et al., 2013; Oltica et al., 2007; Zuluaga et al., 2015.

[0045] The starting material of the process described herein is based on or consists of pollen. Suitable pollen can be fresh or dehumidified. The latter is more suitable for carrying out the process on an industrial scale.

[0046] Suitable dehumidified pollen is pollen that has been subjected to drying after collection, for example with a hot air current, so that the percentage of moisture is below 12%. A low percentage of water, for example below 0.5 relative humidity, makes the pollen a sufficiently stable material if properly packaged and stored.

[0047] Typically, the dehumidified pollen is in the form of granules, the color of which is a function of the species or different plant species visited by the bees.

[0048] By way of example, suitable dehumidified multi-floral pollen has the following organoleptic characteristics: - Appearance: Small grains, varying in color depending on the plant species of origin. - Smell: vegetables, dry grass. - Taste: Vegetable, characteristic of dried flowers, hay. Solubility: Slightly soluble in water or organic solvents. - Moisture: 7~15% - Glucid: 25-48% - Protein: 11-28% - Fat: 1-14% - Inorganic salts: 1-5%

[0049] Within the processes described herein, the dehumidified pollen, which typically occurs in the form of granules or agglomerated particles, may be used as is or may be previously treated to break down or destroy the outer shell of the granules and make the inner content available for the fermentation activity of the inoculated microorganism.

[0050] Physical treatments, such as mechanical or biological treatments, can be used to disrupt the coating layer of the pollen grain, which typically contains cellulose, pectic substances, carotenoids and polyphenols.

[0051] Suitable mechanical treatments include crushing, grinding, pulverizing, high pressure and / or ultrasound or heat treatment of the pollen.

[0052] In order to break down the outer wall of the pollen grain, it is possible to fragment or reduce the size of the granules into smaller particles or other techniques which do not substantially alter the nutritional characteristics of the starting matrix or pollen, or which may result in a more nutritious product.

[0053] The breakdown of the outer layer of the pollen grain involves a process for its size reduction and can rely on equipment traditionally used in the food or pharmaceutical industries.

[0054] For example, devices involving the passage of pollen through a metal mesh with appropriate mesh gaps, such as vibrating arm granules, or devices using various types of mills, such as knife, ball bearing, etc., or combinations of these devices can be used.

[0055] Size reduction or comminution of pollen grains can also be accomplished using wet techniques, for example, using four-way mixers with choppers and knives, stator rotor homogenizers immersed in a fluid medium, ultrasonic systems and other commercially available equipment.

[0056] Heat treatment can optionally be used at greater than ambient pressure to allow pasteurization with the aid of high pressure, such as high pressure processing (HPP), or ultrasonication or other processes.

[0057] For example, for heat treatment under pressure, pollen can be conveniently reconstituted in 10% water.

[0058] In the case of ultrasound treatment, pollen may be used as is.

[0059] It is also possible to use as starting material a purified pollen extract obtained from entomophilic pollen which has previously been subjected to one or more solvent extraction steps, such as a mixture of water and alcohol.

[0060] According to some embodiments, the outer coat layer of the pollen is destroyed by biological degradation, for example by treating the pollen with yeast.

[0061] Thus, some embodiments of the invention provide for the addition of yeast that degrades or metabolizes the pectic components that coat the pollen grains. Typically, the addition of yeast may be carried out before or during step a) of the process.

[0062] The added yeast comes into contact with the pollen grains and triggers a process of breakdown of the pollen coat, facilitating contact of the inoculated lactic acid bacteria with the nutrients present inside the grain in step b).

[0063] Typically, the addition of yeast is carried out when the starting pollen has not been processed and in particular has not been subjected to mechanical action such as crushing or grinding aimed at breaking down the covering layer of the kernel.

[0064] According to a preferred embodiment, the yeasts which degrade or metabolize the pectic components coating the pollen grains belonging to the species Wickerhamomyces anomalus or Hanseniaspora uvarum are a mixture of two species.

[0065] According to one embodiment, the yeast used is Hanseniaspora uvarum strain AN8Y27B.

[0066] In an embodiment of the process of the present invention, the inoculum is prepared using pollen itself as the growth substrate.

[0067] In other embodiments, the growth substrate for the inoculated microorganism is a suitable culture medium, such as fructose-yeast-peptone, FYPed, optionally containing yeast or vegetable extracts and peptones, which provide the microorganism with the nutrients necessary for rapid growth.

[0068] Alternatively, a mixture of pollen and extracts / peptones can be used.

[0069] In a preferred embodiment of the process of the present invention, the inocula of lactic acid bacteria and yeast are prepared separately.

[0070] The fermentation b) step of the process is carried out by inoculation with a lactic acid bacterium typically belonging to the genus Lactobacillus, conveniently the species Lactobacillus kunkeei.

[0071] According to a preferred embodiment, step a) comprises inoculation of lactic acid bacteria belonging to the species Lactobacillus kunkeei, selected from the Lactobacillus kunkeei PF12, PF15 and PL13 strains and mixtures thereof. Each of these selected bacterial strains has an unexpectedly higher capacity of growth and colonization on pollen-based substrates than other lactobacilli also belonging to the species Lactobacillus kunkeei. Moreover, as demonstrated in the experimental section reported in the following examples, said three strains have a surprising ability to acidify and produce antibacterial compounds.

[0072] Advantageously, the fermentation step of the method of the invention is carried out in a bioreactor, typically under aerobic conditions.

[0073] According to some embodiments, the humidity of the product inside the bioreactor ranges from 30-95% of the total mass.

[0074] Typically, the mixture containing the pollen and the inoculated microorganisms may be in a semi-solid form, e.g., 30-45%, when the humidity value is low, and in a semi-solid or liquid form, e.g., 60-95%, when the humidity value is high.

[0075] According to some embodiments, the pH of the environment in the bioreactor at the beginning of fermentation step b) is in the range of 4-6.

[0076] In a preferred embodiment of the invention, the pH of the system has a value between 5.25 + / - 0.25 and may be corrected within said range by the addition of conventional pH correctors.

[0077] Typically, the following reaction parameters and conditions are monitored during step b) providing: - Amount of sugars (glucose and fructose) - Total titratable acidity - pH - Lactic and acetic acid - Cell density

[0078] When the desired amount of organic acids / cell density / free phenolic acids / residual sugars / free amino acids is obtained, the process can be stopped.

[0079] In an embodiment of the method of the invention, the obtained fermented pollen is subjected to a step c) of reducing the microbial load. According to one embodiment, the obtained fermented pollen is optionally subjected to step c) and subjected to a low temperature drying step, for example typically low temperature drying in a lyostat. Alternatively, the fermented pollen may be conveniently stored frozen after centrifugation, for example at temperatures of the order of -40°C or lower.

[0080] In another embodiment of the invention, the fermented pollen is freeze-dried to keep the microorganisms viable and maintain life. Alternatively, the resulting fermented pollen or biomass may be stored frozen at temperatures below 0, for example at temperatures below -40°C, typically after centrifugation.

[0081] For the purposes of the present invention, other conventional techniques can also be used to remove water from the fermented pollen, for example by resorting to spray drying.

[0082] According to one embodiment, the process of the invention comprises the steps of: - a supply of a starting material based on fresh, non-pretreated pollen, preferably stored at -20°C or based on dried or dehumidified pollen, conveniently stored at +4°C or at room temperature and / or optionally pretreated by grinding, pulverizing, micronizing, heat treatment, high pressure and / or ultrasonic treatment, or a pollen extract; - optional dilution with distilled water and correction of the pollen pH value to reach a value of 5.25 ± 0.25; - inoculation of a cell suspension containing lactic acid bacteria selected from L. kunkeei PF12, PF15 and PL13 or a mixture thereof, and inoculation of a yeast having pectinolytic activity belonging to the genus Wickerhamomyces or the species Hanseniaspora uvarum, for example strain AN8Y27B; - Distilled water is usually added until a final humidity of 30-95% is reached. Typically, the final moisture value also includes the initial moisture content of the pollen, which is for example equal to about 21.56%, and the water added during the inoculation stage. - Incubate in sterile tubes or bioreactors preferably at 30°C for 24-216 hours and isolate fermented pollen.

[0083] According to some embodiments, the fermented pollen obtained from the above process can be freeze-dried in a lyostat or frozen at a temperature of about -20°C or below, preferably after centrifugation.

[0084] In certain embodiments, the fermented pollen may be subjected to other treatments to reduce the microbial load, remove water, or stabilize the fermented pollen.

[0085] According to a second aspect, the present invention provides bee bread or fermented pollen obtained by the process according to any one of the embodiments described herein. The fermented pollen obtained by the method of the present invention has a higher level of free water-soluble phenolic compounds than the starting pollen. These and other features are described in detail in the following examples.

[0086] In another embodiment of the invention, the liquid fraction possibly resulting from step b) of the fermentation is separated from the solid components and used for food, dietary or nutritional purposes.

[0087] Both the liquid and solid fractions may find nutritional use.

[0088] According to a third aspect of the present invention, a nutritional or nutritional composition is provided comprising fermented pollen obtained according to any one of the embodiments described herein and an edible carrier.

[0089] According to a fourth aspect there is provided a composition comprising lactic acid bacteria belonging to Lactobacillus kunkeei strains, Lactobacillus kunkeei PF12, PF15 and PL13 strains and mixtures thereof, and an edible carrier.

[0090] The bacterial strains of the composition may be in live and viable or inactivated form according to conventional techniques, for example by tindarization.

[0091] The compositions described herein are suitable for oral administration.

[0092] The compositions for oral administration may be in solid or liquid form. In the case of solid form, they contain the bee bread obtained from the process described herein as a biologically active ingredient and one or more physiologically acceptable excipients.

[0093] Typical solid form compositions include tablets, granules, capsules, powders, immediate dose forms, candies, chewing gums, jelly beans of different compositions and shapes.

[0094] The present invention applies to any solid, semi-solid and liquid dosage form that can serve as an edible carrier for administration of the present invention.

[0095] The present invention applies to all dosage forms that require dilution or use of the formulation prior to administration, whether in solid, semi-solid or liquid form.

[0096] Tablets generally contain a suitable carrier or excipient in which the plant extract is dispersed, typically in dry form.

[0097] In this case, suitable excipients for inclusion in the formulation are cellulose derivatives such as hydroxymethylcellulose, hydroxypropylmethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, carboxyethylcellulose, ethylhydroxyethylcellulose, cellulose acetate butyrate, cellulose acetate phthalate, and mixtures thereof.

[0098] Further examples of suitable excipients include polymers belonging to the lactam family, such as pyrrolidone and its derivatives, such as polyvinylpyrrolidone, polyvinylpolypyrrolidone and mixtures thereof, inorganic salts, such as calcium or dicalcium phosphate, lubricants, such as magnesium stearate, triacylglycerols and mixtures thereof.

[0099] In the case of liquid form, the composition contains the liquid fraction separated at the end of fermentation step b) as biologically active ingredient and one or more physiologically acceptable excipients.

[0100] Typical compositions in liquid form include solutions, emulsions, suspensions, and syrups.

[0101] The bee bread or fermented pollen obtained by the method of the invention contained in the composition of the invention may be present in various amounts, for example in the range of 0.0001% to 100% by weight, 0.001% to 50% by weight, 0.1% to 20% by weight, typically 0.5 to 5% by weight.

[0102] According to certain embodiments, the compositions of the present invention further comprise one or more active agents, such as vitamins, minerals, micronutrients and other active agents.

[0103] According to some embodiments, the composition for oral administration is a functional food, a nutraceutical composition, a dietary product, a complement or a nutritional product.

[0104] The compositions may be commercially available in conventional dosage forms such as heat resistant aluminum pouches of the type or stick packs containing solid ingredients, or dispersions of solid ingredients in liquids, containers for modern reconstitution of solids in liquids, hard or soft capsules containing solids dispersed in food grade oil or other compatible liquids, vials or bottles containing dispersions of solids in liquids.

[0105] According to some aspects, the present invention relates to bee bread obtained by any one of the process embodiments described herein or compositions containing it for use in treating metabolic, cardiovascular, bone, brain or gut microbiome functionality or for use as a driver of gut microbiome functionality.

[0106] According to another aspect, the present invention provides the use of bee bread, for the treatment of hair, in particular for the treatment of the skin by oral ingestion or cosmetic use, of a composition obtained according to or containing any one of the embodiments of the method described herein, in particular as an anti-ageing treatment or to reduce skin ageing.

[0107] The bee bread obtained by the process of the present invention has cellular antioxidant activity and is used in the prevention or treatment of diseases resulting in the non-physiological production of free radicals, typically tumors, precancerous diseases or sun-related diseases, such as sunburn, skin spots, roughness or reddening conditions as a result of skin aging. Furthermore, the bee bread of the present invention finds application in maintaining individual organisms in a state of physiological health.

[0108] According to a further aspect, the present invention provides selected lactic acid bacteria belonging to the species Lactobacillus kunkeei selected from PF12, PF15 and PL13, and mixtures thereof.

[0109] The present inventors have selected Lactobacillus kunkeei strains PF12, PF15, and PL13 for the production of antibacterial compounds as shown in Tables 2 and 3 below, for their surprisingly improved ability of growth, acidification as shown in Table 1 below, compared to other strains belonging to the same species.

[0110] As an example, the protocol used for the selection of Lactobacillus kunkeei PF12, PF15, and PL13 bacterial strains is described below. The protocol described in more detail in Example 1 below involves testing bacterial strains isolated from flowers, pollen, bee brood, and the gastrointestinal tract of bees.

[0111] The identified strains were tested for their growth, acidification and ability to produce antibacterial compounds.

[0112] Aqueous pollen extract was used as a model system for bacterial growth. The pollen extract was obtained by the following procedure.

[0113] One hundred grams of pollen was added along with glass beads, mixed with 1 liter of distilled water, and stirred at 500 rpm for 2 hours. The mixture was centrifuged at 10,000×g for 20 minutes. The supernatant was collected and the residue was further extracted successively with 1 liter of acidified methanol (0.1% HCl, v / v), a mixture of hexane / acetone / ethanol 50:25:25 (v / v / v), and boiling water, respectively, as described above. All extracts were dried, dissolved in 10 ml of dimethyl sulfoxide (DMSO), mixed together, and further diluted in distilled water to a final volume of 1 liter. The pollen extract was sterilized by sterile filtration on a membrane with porosity of 0.22 μm. The strains were inoculated individually at a final cell density of approximately 7.0 log CFU / ml, and the pollen extract was incubated at 30°C for 24 hours. Growth and acidification were monitored, and the growth and acidification kinetics of the strains were mathematically modeled using the Gompertz equation. The antibacterial activity of the strains was tested against eight aggravating or pathogenic indicator bacteria and eight indicator fungi. To test the antibacterial activity of the strains, the lactic acid bacteria were grown in pollen extract for 24 h at 30°C, the supernatant was harvested by centrifugation at 10,000 x g for 10 min at 4°C and sterilized by sterile filtration on a membrane of 0.22 μm porosity. Antibacterial activity was assayed by agar diffusion wells, while antifungal activity was assayed by agar dilution assay.

[0114] Table 1 below shows the optical density, DO, expressed as pH change (ΔpH) in pollen extracts fermented for 24 hours at 30°C with lactic acid bacteria strains belonging to different species and isolated from flowers, pollen, bee breds and the digestive tract of honey bees. 620 Data are shown for cell density expressed as sucrose and acidification.

[0115] [Table 1(1)] [Table 1(2)] [Table 1(3)] [Table 1(4)]

[0116] As can be seen from the experimental data, the selected Lactobacillus kunkeei strains PF12, PF15 and PL13 have surprisingly higher growth and acidification capacities than those observed for the other tested strains belonging to the same bacterial species.

[0117] Table 2 below shows the inhibition spectrum of the pollen extract fermented with a lactic acid bacteria strain at 30°C for 24 hours. * Pathogenic or aggravating indicator bacteria ‡ The antibacterial activity against 8 strains was examined. Unfermented pollen extract was used as a control.

[0118] [Table 2(1)] [Table 2(2)]

[0119] Table 3 below shows the inhibition spectrum of the pollen extract fermented with lactic acid bacteria at 30°C for 24 hours. * The indicator bacteria are shown below. ‡ Antifungal activity against eight strains was examined. The percentage of inhibition of mycelial growth was calculated with respect to the growth of indicator strains on potato dextrose agar (PDA) supplemented with unfermented pollen extract.

[0120] [Table 3(1)] [Table 3(2)]

[0121] The experimental data in Tables 2 and 3 further highlight that the selected Lactobacillus kunkeei strains PF12, PF15, and PL13 have surprisingly higher antibacterial activity than that found for other strains tested, belonging to the same or other bacterial species.

[0122] term In the present context, the term pollen means the entomophilous pollen collected by foraging bees and processed by them; said pollen may come from a single plant species (haploid) or from several plant species (polymorphic).

[0123] By functional food is meant any modified food or food ingredient that may provide a benefit or protection against a problem or physiological condition in addition to the conventional nutrients contained therein.

[0124] "Nutraceutical" refers to a product isolated or purified from a dietary substance. A dietary supplement is one that has a physiological benefit or that has been shown to provide protection against a problem or physiological disorder.

[0125] Dietary supplement means a product containing vitamins, minerals, botanical extracts, amino acids, metabolites, extracts, concentrates or mixtures of these ingredients.

[0126] The term "edible carrier" means any edible carrier that may be used in the formulation of a food, dietary supplement, or dietary / food supplement.

[0127] Within the scope of this description, the terms bee bread and fermented pollen obtained by the method of the invention denote the same product and are interchangeable.

[0128] The organoleptic and / or nutritional properties of traditional bee bread, as described in the previous chapter dedicated to the prior art, are substantially similar to those of the fermented pollen obtained by the method of the present invention.

[0129] The following examples are provided for illustrative purposes only of some embodiments of the invention. EXAMPLES

[0130] Example 1 Protocol for the selection of bacterial strains of Lactobacillus kunkeei PF12, PF15 and PL13 To select three strains of lactic acid starter bacteria, 93 bacterial strains belonging to various species and isolated from the gastrointestinal tract of flowers, pollen, bee breds and honeybees were tested for their growth, acidification and antibacterial compound production abilities.

[0131] Pollen extract was used as a model system for bacterial growth and was obtained as follows.

[0132] 100 grams of pollen was added along with glass beads, mixed with 1 liter of distilled water and stirred at 500 rpm for 2 hours. The mixture was centrifuged at 10000×g for 20 minutes. The supernatant was collected and the residue was further extracted successively with 1 liter of acidified methanol (0.1% HCl, v / v), hexane / acetone / ethanol mixture 50:25:25 (v / v / v), and boiling water, respectively, as described above. All extracts were dried, dissolved in 10 ml of dimethyl sulfoxide (DMSO), mixed together, and further diluted in distilled water to a final volume of 1 liter. The pollen extract was sterilized by sterile filtration on a membrane with porosity of 0.22 μm. The strains were inoculated individually at a final cell density of approximately 7.0 log CFU / ml, and the pollen extract was incubated at 30°C for 24 hours. Growth and acidification were monitored, and the growth and acidification kinetics of the strains were mathematically modeled using the Gompertz equation. The antibacterial activity of the strains was tested against eight aggravating or pathogenic indicator bacteria and eight indicator fungi. To test the antibacterial activity of the strains, the lactic acid bacteria were grown in pollen extract for 24 h at 30°C, the supernatant was harvested by centrifugation at 10000 x g for 10 min at 4°C and sterilized by sterile filtration on a membrane of 0.22 μm porosity. Antibacterial activity was assayed by agar diffusion wells, while antifungal activity was assayed by agar dilution assay.

[0133] L. kunkeei strains PF12, PF15, and PL13 were selected because of their good growth ability, acidification ability (Table 1 above), and antibacterial compound production ability (Tables 2 and 3 above).

[0134] Example 2 Fermentation of pollen extracts using lactic acid bacteria The pollen extract obtained according to the protocol described in Example 1 was used as a model system for the growth of 93 lactic acid bacteria, and their growth and acidification abilities were tested. The strains were grown in FYP broth (10 g D-fructose, 10 g yeast extract, 5 g polypeptone*, 2 g sodium acetate, 0.5 g Tween 80, 0.2 g MgSO4·7H2O, 0.01 g MnSO4·4H2O, 0.01 g FeSO4·7H2O, 0.01 g NaCl [pH 6.8] per liter of distilled water) for 24 hours at 30°C. The cells were harvested by centrifugation (10000×g for 10 min at 4°C), washed twice with 50 mM phosphate buffer pH 7.0 and suspended in the pollen extract to a final density of approximately 7 LogCFU / ml. The pollen extract was then incubated for 24 hours at 30°C. Growth (optical density, DO) was measured at 10°C for 10 min at 30°C. 620 ) and acidification (pH change, ΔpH) were monitored during incubation.

[0135] result Ninety-three strains of lactic acid bacteria belonging to various species were tested for their ability to grow and acidify in pollen extract (Table 1). 620 1.473–2.102) and the highest acidification capacity was found in pollen extracts fermented with strains belonging to the species Lactobacillus kunkeei (Table 1).

[0136] Example 3 Antimicrobial activity of pollen extracts fermented with selected lactic acid bacteria strains To test the ability of lactic acid bacteria to produce antibacterial compounds during pollen fermentation, bacteria were grown in pollen extract as described in Example 1, the supernatant was collected by centrifugation (10000×g for 10 min at 4° C.) and sterilized by sterile filtration on a membrane with porosity of 0.22 μm. The antibacterial activity of the extracts was assayed by diffusion assay from agar wells. The analysis was performed in two layers consisting of 15 ml agar-water (2% agar, w / v) and 5 ml specific agar medium for the growth of the indicator strain (Table 2), inoculated to a cell density of approximately 4 LogCFU / ml with cells recovered from a culture of the indicator strain incubated for 24 h at the optimal growth temperature. The wells (5 mm diameter) were double-layered and 100 μl of fermented and cell-free pollen extract was added to each well. Unfermented pollen extract was used as a control. The plates were stored at 4° C. for 1 h to allow radial diffusion of the pollen extract and incubated at 30 or 37° C. for 24 h. The antifungal activity of the extracts was assayed by agar dilution assay to evaluate the radial growth rate of fungal mycelium used as an indicator (Table 3). Fermented and cell-free pollen extracts were added to growth medium (potato dextrose agar, PDA) at a concentration of 30% (v / v) and 15 ml of medium were poured into Petri dishes (diameter 90 mm). Control plates contained only PDA without the addition of pollen extract. The assay was performed by placing a mycelium cap of 3 mm diameter in the center of a Petri dish containing culture medium. After 8 days of incubation at 25 °C in aerobic conditions, the radial growth of the mycelium (diameter mm) was measured. The growth inhibition percentage is calculated as follows: [(mycelium growth in control - mycelium growth in the presence of pollen extract) / mycelium growth in control] × 100. The results are expressed as the average of at least four measurements of mycelial growth.

[0137] result The fermented pollen extract had high antibacterial and antifungal activity, significantly higher than the unfermented pollen extract (P<0.05) (Tables 2 and 3). The use of L. kunkeei strains PF12, PF15 and PL13 in the form of a mixed starter ensured the broadest inhibitory spectrum.

[0138] Example 4 Protocol for preparation and inoculation of cultures of Lactobacillus kunkeei PF12, PF15, and PL13 1) Grow L. kunkeei strains PF12, PF15, and PL13 in FYP broth (10 g D-fructose, 10 g yeast extract, 5 g polypeptone*, 2 g sodium acetate, 0.5 g Tween 80, 0.2 g MgSO4·7H2O, 0.01 g MnSO4·4H2O, 0.01 g FeSO4·7H2O, 0.01 g NaCl per liter of distilled water [pH 6.8]) at 30°C for 24 hours. 2) Centrifuge each culture broth at 10,000 xg for 10 minutes at 4°C. 3) The supernatant is removed and the cells are resuspended in physiological solution (9 g / l NaCl). 4) Centrifuge each cell suspension at 10,000 x g for 10 minutes at 4°C. 5) The supernatant is removed and the cells are resuspended in physiological solution (9 g / l NaCl). 6) Centrifuge each cell suspension at 10,000 x g for 10 minutes at 4°C. 7) The supernatant is removed and the cells are resuspended in physiological solution (9 g / l NaCl). 8) Each cell suspension is read in a spectrophotometer at a wavelength of 620 nm on a cuvette containing 100 μl of cell suspension and 900 μl of water to a cell density of 9 LogCFU / ml, corresponding to an optical density of 0.25. 9) Add the cell suspension of each strain in a ratio of 1:10 to the pollen (previously thawed and brought to room temperature) to obtain a final inoculum equivalent to 8 LogCFU / g. *Polypeptone may be replaced with other protein hydrolysates (e.g. peptone, meat extract, tryptone).

[0139] Example 5 Protocol for preparation and inoculation of cultures of Wickerhamomyces anomalus or Hanseniaspora uvarum AN8Y27B or other yeasts belonging to the genera Wickerhamomyces or Hanseniaspora: 1) Grow Wickerhamomyces anomalus or Hanseniaspora uvarum AN8Y27B, or another yeast belonging to the genus Wickerhamomyces or Hanseniaspora, in yeast extract peptone dextrose broth (YPD, Oxoid) at 30°C for 48-72 hours. 2) Centrifuge the culture broth at 10,000 x g for 10 minutes at 4°C. 3) The supernatant is removed and the cells are resuspended in physiological solution (9 g / l NaCl). 4) Centrifuge the cell suspension at 10,000 x g for 10 minutes at 4°C. 5) The supernatant is removed and the cells are resuspended in physiological solution (9 g / l NaCl). 6) Centrifuge the cell suspension at 10,000 x g for 10 minutes at 4°C. 7) The supernatant is removed and the cells are resuspended in physiological solution (9 g / l NaCl). 8) The cell suspension is read in a spectrophotometer at a wavelength of 600 nm on a cuvette containing 100 μl of cell suspension and 900 μl of water to a cell density of 7 LogCFU / ml, which corresponds to an optical density of 0.1. 9) Centrifuge the cell suspension at 10,000 x g for 10 minutes at 4°C, remove the supernatant, and resuspend the cells in a volume 100 times lower than the original volume. 10) Add the cell suspension of the strain to the pollen (previously thawed and brought to room temperature) in a ratio of 1:10 to obtain a final inoculum equivalent to 8 LogCFU / g.

[0140] Example 6 Protocol for preparation and inoculation of Lactobacillus kunkeei PF12, PF15, and PL13 cultures 1) Grow L. kunkeei PF12, PF15, and PL13 in FYP broth (10 g D-fructose, 10 g yeast extract, 5 g polypeptone*, 2 g sodium acetate, 0.5 g Tween 80, 0.2 g MgSO4·7H2O, 0.01 g MnSO4·4H2O, 0.01 g FeSO4·7H2O, and 0.01 g NaCl per L of distilled water [pH 6.8]) for 24 h at 30 °C for preparation of preinoculum. 2) Transfer 10% of the pre-inoculum culture of each strain in a growth medium prepared with dried pollen in granules and stored at +4°C, pre-treated with a mill or granulator to at least partially destroy the outer coat layer of the granules, resuspend in sterile demineralized water at a concentration of 10-20% (w / w), bring to a pH value of 5.25 ± 0.25 and incubate at 30°C for 24 hours. 3) Inoculate the bioreactor with a culture of each strain in a ratio of 1:10 to obtain a final inoculum corresponding to 7-8 LogCFU / g. The growth medium is prepared by drying the pollen in granules, stored at +4°C, pretreated to weaken the outer wall of the granules as described in point 1, and resuspended in sterile demineralized water to a concentration of 10-20%. *Polypeptone may be replaced with other protein hydrolysates (e.g. bacteriological peptone, meat extract, tryptone).

[0141] Example 7 Fermentation of fresh pollen using a mixed starter composed of selected strains Lactobacillus kunkeei PF12, PF15 and PL13 and yeast Hanseniaspora uvarum AN8Y27B 1) Ingredients: Unprocessed fresh pollen stored at -20℃ 2)10 8 Inoculation of mixed starter consisting of L.kunkeei PF12, PF15 and PL13 and H.uvarum AN8Y27B inoculated at a cell density of CFU / g. The culture preparation and inoculation protocols of L.kunkeei PF12, PF15 and PL13 and H.uvarum AN8Y27B are described in Examples 4 and 5. 3) Add distilled water until the final humidity is 40% (the final humidity value must include the initial moisture content of the pollen [approximately 21.56%] and the moisture added during the inoculation step). 4) Incubate in a 50 ml sterile tube at 30°C for 216 hours.

[0142] result A fermentation protocol for fresh pollen was defined, which included inoculation of a mixed starter composed of selected strains of Lactobacillus kunkeei PF12, PL13 and PF15, and Hanseniaspora uvarum AN8Y27B to a density of 8 LogCFU / g and incubation at 30 °C with a final pollen humidity of 40% for 216 h. Growth and acidification of lactic acid bacteria during incubation was monitored during fermentation by plate counting on FYP agar medium and by measuring titratable acidity (TTA) (Figure 1). Cell density of TTA lactic acid bacteria was monitored during spontaneous fermentation of non-inoculated pollen (control), treated under the same conditions except for the mixed starter inoculation (Figure 1). Upon addition of the selected mixed starter, the cell density of lactic acid bacteria in pollen increased to approximately 9 LogCFU / g after 96 h. -1 and remained constant up to 144 h, increasing by approximately 7 LogCFUg during the remaining incubation time. -1 Otherwise, during spontaneous fermentation of pollen, lactic acid bacteria were only found to be around 9 LogCFU g after 120 h. -1 and rapidly increased to a density of 4 LogCFUg during the remaining incubation period. -1 The increase in TTA during fermentation coincided with the growth of lactic acid bacteria. During spontaneous pollen fermentation, acidification was slower and less intense (P<0.05) than in fermentations performed with the selected mixed starters.

[0143] Example 8 Pollen Fermentation Protocol 1) Raw material: fresh pollen that has not been pretreated and has been stored at -20°C or that has been dried or dehumidified and pretreated by grinding and correcting the pH value of the pollen until it reaches a value of 5.25 + / - 0.25, stored at +4°C or at room temperature; 2)10 7 Inoculation of a mixed starter consisting of selected lactic acid bacteria L. kunkeei PF12, PF15 and PL13, and yeast Wickerhamomyces anomalus, at a cell density of CFU / g. 3) Add distilled water to a final humidity of 70%. 4) Incubate in a sterile test tube or bioreactor at 30°C for 60 hours.

[0144] The fermented pollen is freeze-dried in a lyostat.

[0145] Example 9 Pollen fermentation protocol in bioreactors using selected Lactobacillus kunkeei strains PF12, PF15 and PL13 without yeast inoculation by mechanical pretreatment 1) Raw material: Pollen dried in granules and stored at +4°C, mechanically pretreated in a mill or granulator, the outer wall of the granules broken down and resuspended in a bioreactor in sterile demineralized water to a concentration of 10-20% (w / w) to a final volume of 5 L. 2) Correction of the pH value to reach a value between 5.25 + / - 0.25. 3)10 7 ~10 8 Inoculation of starters composed of L. kunkeei PF12, PF15 and PL13 at cell densities of CFU / g. Protocols for preparation and inoculation of cultures of L. kunkeei PF12, PF15 and PL13 are described in Example 6 below. 4) Incubate at 30°C for 2-4 days with stirring at 70-100 rpm to keep the fermentation medium homogenous. 5) The fermented pollen is either freeze-dried in a lyostat (9A) or spray-dried to dryness (9B).

[0146] Example 10 Pollen fermentation protocol in bioreactors using selected Lactobacillus kunkeei strains PF12, PF15 and PL13 without yeast inoculation by thermal pretreatment 1) Raw material: dehumidified pollen in granules, heat pretreated (121 °C, 15') and resuspended in sterile demineralized water at a concentration of 10-20% (w / w) in a bioreactor to a final volume of 5 L. 2) Correction of the pH value to reach a value between 5.25 + / - 0.25. 3)10 7 ~10 8Inoculation of starters composed of L. kunkeei PF12, PF15 and PL13 at cell densities of CFU / g. Protocols for preparation and inoculation of cultures of L. kunkeei PF12, PF15 and PL13 are described in Example 6 below. 4) Incubate at 30°C for 2-4 days with stirring at 70-100 rpm to keep the fermentation medium homogenous. 5) The fermented pollen is either freeze-dried in a lyostat (10A) or spray-dried to dryness (10B). Inoculation of starters composed of L. kunkeei PF12, PF15, PL13 Protocols for preparation and inoculation of cultures of L. kunkeei PF12, PF15, and PL13 are described in Example 6 below. Incubate at 30 °C for 2-4 days with agitation at 70-100 rpm to keep the fermentation medium homogenous. The fermented pollen is dried by freeze-drying in a lyostat (10A) or by spray drying (10B).

[0147] Example 11 Nutritional enrichment of fermented pollen with a mixed starter composed of selected strains Lactobacillus kunkeei PF12, PF15 and PL13 and yeast Hanseniaspora uvarum AN8Y27B The fermented pollen obtained according to the protocol described in Example 7 was characterized from a chemical and nutritional point of view. The single, total and free amino acid content in the pollen was measured by a Biochrom 30 Amino Acid Analyzer (Biochrom Ltd., Cambridge Science Park, England) equipped with a cation exchange column (Figure 2). The digestibility of the pollen proteins was estimated using a multiphase protocol simulating in vitro digestion (Figure 3). Furthermore, the peptide profile of the pollen was analyzed using an AEKTA FPLC system equipped with a Superose 12 10 / 300 GL column and a 214 nm UV detector (Figure 3). The content in beneficial phenolic compounds soluble in water and methanol was measured by the Folin-Ciocalteu method (Figure 4).

[0148] result Fermented pollen with mixed starters consisting of Lactobacillus kunkeei PF12, PL13 and PF15, and Hanseniaspora uvarum AN8Y27B (Fig. 2) and peptides (Fig. 3) showed approximately 14 and 12 g kg−1 yields, respectively, compared to fresh pollen. -1 A significant increase (P<0.05) in total free amino acids (dry weight) was observed. Furthermore, fermented pollen showed a greater (P<0.05) content in digestible protein (75.14±0.7%) compared to fresh pollen (62.11±0.8%) (Figure 3). Furthermore, fresh pollen (8.43±0.85 and 45.73±4.81 g gallic acid eq.kg dry weight) showed a greater increase (P<0.05) in total free amino acids (P<0.05) compared to fresh pollen (62.11±0.8%) (Figure 3). -1 ), fermented pollen showed water-soluble (15.98 ± 0.64 g gallic acid eq. kg dry weight) and methanol-soluble (69.53 ± 4.52 g gallic acid eq. kg dry weight) -1 ) higher concentrations of free phenolic compounds (P<0.05) were found.

[0149] Example 12 1. Experimental Testing 2. Purpose of the Experiment The experimental procedure reported below aims to investigate the in vitro activity of different strains of fermented pollen (bee bread) and to characterize its antioxidant and anti-inflammatory activity (TNF-α) on human keratinocytes.

[0150] 3.Material 3.1 Test Sample [Table 4] *The starters selected consisted of L. kunkeei PF12, PF15, and PF3, and Wickerhamomyces anomalus LCF1695.

[0151] The fermentation product was held at 30° C. for 12 hours.

[0152] All extracts were diluted to 50 mg / ml in medium (100% solution solubility stocks) and sterile filtered (5 mg / mL). Stocks were stored at -20°C.

[0153] 3.2 Reagents and equipment used [Table 5]

[0154] [Table 6]

[0155] 3.3 Biological model used 3.3.1 Culture of human keratinocytes An immortalized line of human keratinocytes NCTC2544 was used (Perry VP et al., 1957), cultured in sterile flasks (25 cm3) and incubated at 37°C in a humidified atmosphere of 5% CO2 in RPMI culture medium supplemented with 2 mM glutamine in the presence of fetal bovine serum (FBS), 1% penicillin and streptomycin and 0.1% gentamicin.

[0156] 1:3 split into 1XPBS (Ca 2+ and Mg 2+ Every 2 days after achieving a monolayer, cells were washed with trypsin-EDTA (phosphate buffered saline free) and detached with trypsin-EDTA solution for 2 min at 37° C. The cells were kept in culture in sterile flasks of 25 cm3 and incubated at 37° C. in a humidified atmosphere of 5% CO2.

[0157] [Table 7]

[0158] 3.3.2 Control 3.3.2.1 Induced oxidative stress MTT assay Negative control: untreated cells in RPMI supplemented with 2.5% fetal bovine serum (FBS), 2 mM glutamine were kept in (96-well) culture plates at 37°C and 5% CO2 (in the dark) in the presence of 1% penicillin and streptomycin and 0.1% gentamicin.

[0159] Positive control: cells treated with 1 mM hydrogen peroxide for 2 h in RPMI supplemented with 2.5% fetal bovine serum (FBS), 2 mM glutamine, and kept in (96-well) culture plates at 37°C and 5% CO2 (in the dark) in the presence of 1% penicillin and streptomycin and 0.1% gentamicin.

[0160] 3.3.2.2 Anti-inflammatory activity test Negative control: Untreated cells were incubated in RPMI supplemented with 2.5% fetal bovine serum (FBS), 2 mM glutamine in the presence of 1% penicillin and streptomycin and 0.1% gentamicin at 37 °C and 5% CO at 25 cm 2 The cells were stored in a culture plate (12 wells).

[0161] Positive control: Untreated cells were incubated in RPMI supplemented with 2.5% fetal bovine serum (FBS), 2 mM glutamine, 1% penicillin and streptomycin and 0.1% gentamicin in the presence of 10 μg / mL LPS at 37 °C and 5% CO at 25 cm 2 The cells were stored in a culture plate (12 wells).

[0162] 4. Method 4.1 Study of protection against oxidative stress induced in human keratinocyte line NCTC2544 4.2.1 Principle of the method A study carried out in 2005 by Rajapakse and co-workers (2005) demonstrated the possibility of using a highly used and versatile method such as the MTT assay to study the in vitro antioxidant activity of active compounds. Specifically, this method makes it possible to study the protective effect of such compounds on cells subsequently exposed to oxidative stress. The induction of oxidative stress is carried out by incubation with hydrogen peroxide, an agent that induces the production of oxidative damage in cells through the formation of ROS. Any protective effect can be determined through the evaluation of cell viability after oxidative stress of cells pretreated / preexposed to the active compound to be tested, compared to cells exposed to the same oxidative stress. A higher cell viability would correspond to a protective effect of the tested compound.

[0163] 4.2.2 Experimental procedure The assay was performed according to the method described by Coda and coworkers (Coda et al., 2012) with minor modifications.

[0164] Human keratinocytes NCTC2544, 5 x 10 4 Cells were seeded into 96-well plates at a density of 100 cells / well and incubated at 37° C. with 5% CO until they reached approximately 80% confluence.

[0165] The cells were then incubated for 16 hours with the active compounds to be tested and the respective controls at concentrations of 100-250 and 500 μg / mL for sample B, FER867, FER868, FER869, FER870 and FER871, respectively.

[0166] Dilutions were prepared starting from a 50 mg / mL stock in DMSO, sterile filtered, and using RPMI medium supplemented with 2.5% fetal bovine serum (FBS), 2 mM glutamine, in the presence of 1% penicillin and streptomycin and 0.1% gentamicin.

[0167] Cells treated with 1 mM H2O2 were used as a positive control, whereas cells kept in culture alone (RPMI 2.5% FBS) were used as a negative control.

[0168] Alpha tocopherol was tested as the benchmark antioxidant at concentrations of 100, 250 and 500 μg / ml, respectively.

[0169] After 16 h of pretreatment, cells were washed with PBS 1X and incubated for 90 min in 1 mm H2O2 solution (Sigma-Aldrich, St. Louis, MO, USA) at 37°C and 5% CO2 in the dark.

[0170] Once the oxidative stress induction phase was finished, the cell viability of the different samples was assessed according to the method described in point 4.1.2 (MTT assay).

[0171] Data were expressed as percentage of cell viability compared to non-stressed control cells (ctr) according to the following formula: % Cell viability / ctr=(Abs sample / Absctr)*100

[0172] All tests were performed at least twice and in duplicate.

[0173] 4.3 Anti-inflammatory activity (TNF-α) 4.4.1 Experimental procedure Gene expression of TNF-α inflammatory markers in NCTC2544 cells was assessed by relative quantitative RT-PCR (quantitative reverse transcription polymerase chain reaction-qRT-PCR).

[0174] This analysis involved three sequential steps: Total RNA extraction; · Reverse transcription of cDNA; qRT-PCR.

[0175] Human keratinocytes NCTC2544, 0.5 x 10 6Cells were seeded at a density of 100 cells / well into 12-well plates and incubated until they reached approximately 80% confluence.

[0176] The cells were then incubated with sample B, FER867, FER868, FER869, FER870 and FER871 at concentrations of 100, 250 and 500 μg / mL for 16 and 24 hours, respectively.

[0177] Dilutions were prepared starting from a stock of 50 mg / mL in medium supplemented with 2.5% fetal bovine serum (FBS), 2 mM glutamine (RPMI) in the presence of 1% penicillin and streptomycin and 0.1% gentamicin.

[0178] LPS (lipopolysaccharide) was used as an inducer of inflammation in an amount of 10 μg / mL and was co-incubated with the treatment solutions for 16 and 24 h.

[0179] As a negative control, cells maintained in culture medium alone (RPMI 2.5% FBS) were used.

[0180] Alternatively, cells maintained in culture medium alone (RPMI 2.5% FBS) and 10 μg / mL LPS were used as a negative control.

[0181] After incubation, RNA was extracted.

[0182] Total RNA was extracted from NCTC2544 cells as described by Chomczynski and Mackey (1995) .

[0183] After incubation with the active compounds of interest, the cells were washed with PBS (1x) and finally subjected to the RNA extraction procedure. After extraction, the extracted RNA was quantified using a QiaExpert (Qiagen) instrument and the concentration in μg / mL of total RNA extracted at 260 nm wavelength was calculated.

[0184] Finally, RNA integrity (2 μg / mL) was assessed by electrophoresis on a 1% agarose gel.

[0185] The total RNA was converted into cDNA (complementary DNA) using an enzyme capable of synthesizing a NA molecule using a strand of RNA as a template. This DNA-polymerase RNA-dependent enzyme is called reverse transcriptase.

[0186] It binds to the 3' end of a single strand of RNA and, via random primers and deoxynucleoside triphosphates (DNTPS), it synthesizes a strand of cDNA.

[0187] For this purpose, we used a commercially available kit, "PrimeScript™ RT Reagent Kit (perfect Real Time)" (TakaraBio Inc., Japan), which contains: 5X PrimeScript Buffer (for real-time); PrimeScript RT Enzyme Mix 1; OligodTPrimer; Random 6 mers; RNAse-free 2 dH2O.

[0188] The extracted and quantified RNA was diluted to a concentration of 2 μg / mL and reverse transcribed into cDNA. 10 μL of master mix (5X PrimeScript Buffer (for real-time); PrimeScript RT Enzyme Mix1; Oligonucleotide Primer; Random 6 mers 100 μM) was prepared and 10 μL of RNA (2 μg / ml) was added thereto.

[0189] The samples were placed in a thermal cycler (Stratagene Mx3000P Real Time PCR System, Agilent Technologies Italy SpA, Milan, Italy) and subjected to re-registration under the following conditions: 37 °C, 15 min; 85°C for 5 seconds; Hold at 4℃

[0190] After reverse transcription, 30 μL of DEPC water was added to the samples to give a final concentration of 40 ng / μL of cDNA.

[0191] qRT-PCR is a method for amplifying and quantifying amplification products in real time by monitoring the fluorescence emitted during the reaction.

[0192] The TaqMan® (Applied Biosystems) probe system was used for RT-PCR amplification. The following TaqMan probes were used: Hs00174128_m1 (TNF-α) and Hs99999905_m1 (GAPDH). Hs99999905_m1 was used as a control gene (housekeeping) for GAPDH.

[0193] Taqman probes are a type of probe that allows the development of fluorescence as amplification proceeds. A reporter (fluorophore FAM™) is attached to its 5' end, while a quencher is attached to the 3' end. The proximity between the reporter and the quencher negates the fluorescence signal emission. Only the 5' enonuclease activity of the thermostable DNA polymerase (Taq polymerase) fluorescence is detected, and the accumulation of the amplification product can be evaluated through the increase in the reporter fluorescence, which increases during each cycle.

[0194] A master mix was set up for qRT-PCR as follows: 10μl of "2X Premix Ex Taq"; · 1 μl of "20× TaqMan Gene Expression Assays" (containing two primers and the fluorophore-labeled fluorescent probe FAM™); · 0.4 μl passive reference Rox II; 5 μl DEPC water

[0195] The Master Mix contained 4 μL of cDNA for the target gene and 1 μL of cDNA for the housekeeping gene.

[0196] Amplification was performed 40 times under the following conditions: ·95℃, 30 seconds (Amplitaqactivation); 95℃, 5 seconds (denaturation) · 60°C, 20 s (annealing-extension);

[0197] Each analysis was performed in duplicate.

[0198] The data obtained is 2 -ΔΔCt and thus it was possible to calculate the relative value of the expression of the gene of interest, normalized in comparison to the housekeeping gene and calibrated on the control sample (untreated cells): ΔΔCt=ΔCt target-housekeeping (Control)-ΔCt target-housekeeping (treated cells)

[0199] 2 -ΔΔCt was calculated assuming an amplification rate of 100%.

[0200] 5.Results 5.1 Protection assay against induced oxidative stress FIG. 5 shows data relating to the protective activity against induced oxidative stress of the tested samples in comparison with an antioxidant of known action, α-tocopherol.

[0201] The results show significant protective activity against induced oxidative stress for all compounds analyzed at concentrations of 250 and 500 μg / mL, which activity is comparable to that of α-tocopherol.

[0202] 5.2 Anti-inflammatory activity (TNF-α) The attached Figures 6A and B show the TNF-α gene expression data after treatment with sample B (control), FER867, FER868, FER869, FER870 and FER871 at concentrations of 100-250 and 500 μg / mL, respectively, for 16 hours (Figure 6A) and 24 hours (Figure 6B).

[0203] After 16 hours of treatment, sample B and FER867 tested at concentrations of 100, 250 and 500 μg / mL show the most significant anti-inflammatory activity (FIG. 6A).

[0204] The anti-inflammatory activity is more evident after 24 hours of treatment, especially for the FER867 samples (FIG. 6B).

[0205] 6. conclusion In conclusion, the studies carried out showed a significant protective activity against induced oxidative stress for all samples tested at concentrations of 250 and 500 μg / ml (FIG. 5).

[0206] Furthermore, anti-inflammatory studies showed that sample B, FER867, tested at concentrations of 100 and 250 μg / ml, exhibited significant anti-inflammatory activity after 16 h of treatment (Figure 6A).

[0207] For compound FER869, a concentration of 500 μg / ml significantly reduced TNF-α-related mRNA expression. FER871 at concentrations of 100 and 500 μg / mL shows a decrease in mRNA production. The anti-inflammatory activity of the test compounds is more evident after 24 hours of treatment, especially for compound FER867 (Figure 6B).

[0208] Bibliography Arch Dermatol Res 1976;256(3):255-260- PMID:990102 Arch Dermatol Res 1976;261(1):27-31 Mosmann T, 1983. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. J Immunol Methods 65(1-2), 55-63. Rajapakse N, Mendis E, Byun HG, Kim SK, 2005. Purification and in vitro antioxidative effectsOf giant squid muscle peptidesOn free radical-mediatedOxidative systems.J NutrBiochem 16(9),562-569. Coda R, Rizzello CG, Pinto D, Gobbetti M, 2012. Selected Lactic Acid Bacteria Synthesize Antioxidant Peptides during Sourdough FermentationOf Cereal Flours. Appl Environ Microbiol 78(4), 1087-1096. Chomczynski P,Mackey K.ModificationOf the TRI reagent procedure for isolationOf RNA from polysaccharide- and proteoglycan-rich sources.Biotechniques 1995;19:942-5.

[0209] Example 13 Soft jelly capsule Each soft jelly capsule (pearl) contains: q.ty um Pollen fermented with selected Lactobacillus kunkeei strains PF12, PF15, and PL13 without yeast inoculation, see Example 5 100 mg Soybean oil 250mg Soy lecithin 5mg Mono- and diglycerides of fatty acids 30mg Shell Components: Gelatin 145mg Glycerol 67mg

[0210] Example 14 tablet Each dose contains: q.ty um Pollen fermented with selected Lactobacillus kunkeei strains PF12, PF15, and PL13 without yeast inoculation, see Example 5 200 mg Microcrystalline cellulose 100mg BioGABA [Gamma Aminobutyric Acid from Fermentation of Grape Must (Vitis vinifera L. Fruit), Lactobacillus plantarum C48] 100mg Polyvinylprorolidone 35mg Rice (Oryza sativa L. seed dry extract) 50mg Alfalfa (Medicago sativa L flower dry extract) 40mg Chlorella (Chlorella pyrenoidosa H Chick) leaf dry extract 30mg Phosphatidylserine 40mg Dried extract of leaves and flowers of Melissa (Melissa Officinalis L) 100mg Griffonia simplicifolia (DC) Baill seed dry extract 51mg L-Theanine 12.6mg Silicon dioxide 10mg Magnesium stearate 10mg

[0211] Example 15 Chewable tablets Each dose contains: q.ty um Maltodextrin 50~300mg Dextrose 50~300mg Fructose 50-300mg Pollen fermented with selected Lactobacillus kunkeei strains PF12, PF15, and PL13 without yeast inoculation, see Example 5 100 mg Fragrance 10~30mg Corn starch 10~30mg Microcrystalline cellulose 10-30mg Silicon dioxide 5~15mg Leucine 5-15mg

[0212] Example 16 tablet Each dose contains: q.ty um Calcium phosphate 150mg Pollen fermented with selected Lactobacillus kunkeei strains PF12, PF15, and PL13 without yeast inoculation, see Example 5 50 mg Boswellia (Boswellia serrrata Roxb) dry extract resin 150mg Palmitoylethanolamide (PEA) 150mg BioGABA [Gamma Aminobutyric Acid from Grape Must Fermentation (Vitis vinifera L. Fruit), Lactobacillus plantarum C48] 100mg γ-aminobutyric acid 49mg Turmeric (Curcuma longa L.) dry extract 100mg Microcrystalline cellulose 50mg Vitamin D (cholecalciferol) 0.005mg Vitamin B3 (nicotinamide) 16mg Hydroxypropyl cellulose 30mg Silicon dioxide 6mg Mono- and diglycerides of fatty acids 10mg Vitamin B1 (thiamine mononitrate) 1.36mg Vitamin B2 (riboflavin) 14mg Vitamin B5 (calcium pantothenate) 6.5mg Vitamin B6 (pyridoxine hydrochloride) 1.7mg Vitamin K2 (menaquinone-7) 0.075mg Vitamin B12 (cyanocobalamin) 0.026mg

[0213] Example 17 tablet Each dose contains: q.ty um Ashwagandha (Withania somnifera L Dunal) root dry extract 150mg Pollen fermented using a mixed starter consisting of selected strains Lactobacillus kunkeei PF12, PF15, PL13 and the yeast Hanseniaspora uvarum AN8Y27Bref. See Example 4. 50mg Microcrystalline cellulose 100mg Magnesium oxide 100mg Bacopa (Bacopa monnieri L Pennel) Dry Extract Top 100mg BioGABA [Gamma Aminobutyric Acid from Fermentation of Grape Must (Vitis vinifera L. Fruit), Lactobacillus plantarum C48] 100mg Calcium phosphate 100mg γ-aminobutyric acid 49mg Saffron (Crocus sativus L) flower extract 30mg Hydroxypropyl methylcellulose 30mg Zinc bisglycinate 10mg Silicon dioxide 7mg (6S)5-Methyltetrahydrofolic acid, glucosamine salt 0.2mg Magnesium stearate 11mg

[0214] Example 18 Immune Stimulating BAR 30g Pollen fermented with selected strains Lactobacillus kunkeei PF12, PF15 and PL13 without yeast inoculation, see Example 5 2 g Glucose and fructose syrup 10-14g 10~12g rice pieces Sunflower lecithin 0.5~3g Palm oil (Elaeis guinensis) 0.5~3% Corn maltodextrin 1-2g Akai (Euterpe Oleracea) dehydrated fruit 3~4g Vitis apyrena L. dehydrated fruit 1~2g Citric acid qb aroma qb

[0215] Example 19 Hard jelly capsule Each hard jelly capsule contains: q.ty um Pollen fermented using a mixed starter consisting of selected strains Lactobacillus kunkeei PF12, PF15, PL13 and the yeast Hanseniaspora uvarum AN8Y27Bref. See Example 4. 200mg Maltodextrin 5~50mg Insoluble natural fiber: 5-100mg Magnesium stearate 1~10mg Silicon dioxide 3~6mg Natural jelly coating

[0216] Example 20 Oral water-soluble granules Each sachet contains: q.ty um Pollen fermented using a mixed starter consisting of selected strains Lactobacillus kunkeei PF12, PF15, PL13 and the yeast Hanseniaspora uvarum AN8Y27Bref. See Example 4. 1000mg Inulin 200~600mg Maltodextrin 0.5~3.0g Malic acid 1-10mg Fragrance 10.0~50.0mg Sucralose 0.005mg

[0217] Example 21 Granular blend in stick pack Each sachet contains: q.ty um Pollen fermented with selected Lactobacillus kunkeei strains PF12, PF15, and PL13 without yeast inoculation, see Example 5 500 mg Echinacea (Echinacea purpurea) aerial part dry extract 300mg Honey aroma 10mg Inulin 1~2g Gum arabic 0.5~2g Malic acid 0-100mg Sucralose 0.005mg Fragrance 0.25mg

[0218] Example 22 tablet Each tablet contains: Pollen fermented with selected Lactobacillus kunkeei strains PF12, PF15, and PL13 without yeast inoculation, see Example 5 50 mg Microcrystalline cellulose 50mg Broccoli (BrassicaOleracea italica var) inflorescence dried extract 125mg BioGABA [Gamma Aminobutyric Acid from Fermentation of Grape Must (Vitis vinifera L. Fruit) 100mg Fermented pollen 100mg Mustard (Brassica juncea L Czern) seed dry extract 75mg Artichoke (Cynara scolymus L) leaf dry extract 60mg Acerola (Malpighia glabra L) dried fruit extract 100mg Orange (Citrus sinensis L) fruit dry extract 50mg Calcium phosphate 50mg Beta root (Beta vulgaris L) whole plant dry extract 50mg Hydroxypropyl cellulose 20mg Bayberry (Myrica cerifera L) bark dry extract 30mg Astragalus (Astragalus membranaceus) root dried extract 30mg Quercetin 30mg Vitamin E (tocotrienol tocopherol) 6mg Beta-sitosterol 20mg Lycopene 10mg Nicotinamide 16mg Silicon dioxide 10mg Mono- and diglycerides of fatty acids 10mg Galeopsis (Galeopsis segetum Necker) aerial part dry extract 5mg Spermidine trihydrochloride 0.5mg Biotin 0.05mg

Claims

1. A microbiological process for producing bee bread, comprising the steps of a) inoculating pollen in a pollen grain with a starter lactic acid bacterium and b) fermenting the pollen, said process being characterized in that the inoculated starter lactic acid bacterium is a Lactobacillus kunkeei strain PF12 having the accession number DSM 32843, deposited at the International Depository Centre Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, ... and the Lactobacillus kunkeei strain PL13 having the accession number DSM 32844 deposited at the international depositary centre Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH.

2. 2. The method according to claim 1, comprising a step of pre-treatment of the pollen grains to degrade the outer coating layer and make the contents of the pollen grains available for the fermentation activity of the lactic acid bacteria inoculated in step a).

3. 3. The method of claim 2, comprising inoculating said pretreatment step or step a) with a yeast which degrades or metabolizes the pectin components of the coating of said pollen grains.

4. The method according to any one of claims 1 to 3, comprising a further step c) of reducing the microbial load after the fermenting step.

5. A method according to any one of claims 1 to 4, comprising the further step of drying.

6. 6. The method of claim 5, comprising the further step of freeze-drying or spray-drying.

7. Bee bread or fermented pollen obtained by the method according to any one of claims 1 to 6.

8. A composition comprising the bee bread or fermented pollen of claim 7 and an edible carrier.

9. 9. Bee bread according to claim 7 or a composition according to claim 8 for use in the treatment of cardiovascular diseases, metabolic diseases, bone diseases, brain diseases and intestinal diseases.

10. 9. Bee bread according to claim 7 or a composition according to claim 8 for use in the treatment of skin ageing, for use in the treatment of the skin or for use in the treatment of hair.

11. Lactobacillus kunkeei PF12 having the accession number DSM 32843 deposited at the international depository center Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Lactobacillus kunkeei having the accession number DSM 32845 deposited at the international depository center Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH PF15, and a strain mixture of Lactobacillus kunkeei PL13 having the accession number DSM 32844 deposited at the international depository centre Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH.

12. Lactobacillus kunkeei PF12 having the accession number DSM 32843 deposited at the international depository center Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Lactobacillus kunkeei having the accession number DSM 32845 deposited at the international depository center Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH PF15, and Lactobacillus kunkeei PL13 having the accession number DSM 32844 deposited at the international depository centre Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH.

Citation Information

Patent Citations

  • Method for preparing artificial bee bread

    CN1488282A

  • Novel bacteria isolated from fresh honey or honeybee honey production tubes.

    JP2010525809A

  • Method of modifying bacteria

    WO2012102668A1